Sign up for the latest news from WAMES, straight to your inbox. Read about:
You can also continue to read about key news from around the world on our blog and social media.
Solve ME’s analysis of its You + ME Registry-based population (now Solve Together) sheds light on the complex interplay between joint hypermobility, ME/CFS, and Ehlers Danlos Syndrome.
“Our results showed distinctive clinical characteristics in ME/CFS with joint hypermobility, including a higher likelihood of hereditary hypermobility, reduced health-related quality of life (HRQOL) related to physical functioning and pain, and a range of autonomic, cognitive, headache, gut, and musculoskeletal symptoms.
Sensitivity subgroup analysis underscored the importance of concurrent EDS. In this context, patients with both JH+ ME/CFS and EDS showed more severe symptoms, greater functional limitations, and an increased overall burden of symptoms compared to those with JH+ ME/CFS but without EDS.
These findings emphasize the need for comprehensive clinical assessment and consideration of underlying connective tissue disorders in ME/CFS patients presenting with joint hypermobility. A comprehensive understanding of the clinical features, prognosis, and disease trajectory for these patients could guide cohort selection for research studies and facilitate the discovery of underlying disease mechanisms and targeted therapies.
Further research is needed to understand the implications of joint hypermobility in ME/CFS for research, diagnosis, and clinical care.”
Do people with ME/CFS and joint hypermobility represent a disease subgroup? An analysis using registry data, by Kathleen Mudie, Allison Ramiller, Sadie Whittaker, Leslie E Phillips in Front Neurol 2024 Mar 13:15:1324879. doi: 10.3389/fneur.2024.1324879. eCollection 2024
Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic, multifaceted disease that affects millions globally. Despite its significant impact, the disease’s etiology remains poorly understood, and symptom heterogeneity poses challenges for diagnosis and treatment. Joint hypermobility, commonly seen in hypermobile Ehlers-Danlos Syndrome (hEDS), has been observed in ME/CFS patients but its prevalence and clinical significance within this population are not well-characterized.
Objective: To compare the characteristics of ME/CFS patients with and without joint hypermobility (JH+ and JH-) as assessed using the Beighton scoring system, and to explore whether JH+ ME/CFS patients exhibit distinct disease characteristics, comorbidities, and health-related quality of life (HRQOL).
Methods: The study used cross-sectional, self-reported data from 815 participants of the You + ME Registry. Participants were categorized as JH+ or JH- based on self-assessed Beighton scores and compared across demographics, comorbidities, family history, and symptoms. HRQOL was assessed using the Short Form-36 RAND survey and Karnofsky Performance Status.
Results: 15.5% (N = 126) of participants were classified as JH+. JH+ participants were more likely to be female, report Ehlers-Danlos Syndrome (EDS), Postural Orthostatic Tachycardia Syndrome (POTS), and a family history of EDS. They experienced worse HRQOL, particularly in physical functioning and pain, and a higher number of autonomic, neurocognitive, headache, gut, and musculoskeletal symptoms. Sensitivity analysis suggested that ME/CFS with concurrent JH+ and EDS was associated with more severe symptoms and greater functional impairment.
Conclusion: ME/CFS patients with joint hypermobility, particularly those with EDS, demonstrate distinct clinical characteristics, including more severe symptomatology and reduced HRQOL. These findings highlight the need for comprehensive clinical assessments of ME/CFS patients with joint hypermobility. Understanding these relationships could aid in subgroup identification, improving diagnosis, and informing targeted therapeutic approaches. Further research is warranted to explore these associations and their implications for clinical practice.
Solve ME: New Study Using Solve Real-World Data (RWD) Examines Joint Hypermobility in People with ME/CFS
This research points to the need for comprehensive assessments for ME/CFS patients, potentially leading to quicker and more accurate diagnoses for those with joint hypermobility.
MERUK: Joint Hypermobility and ME/CFS
Limitations of the study include potential selection bias (e.g. individuals with more severe disease may be less likely to participate due to a “burdensome” registry and data collection process), use of optional questionnaires, and self-report data which could be influenced by factors such as recall bias.
We recently bought another 4 more copies of A Physiotherapist’s Guide to Understanding and Managing ME/CFS, which was published in August last year, just a month or so after my Discussion at Dawn with one of its authors, Karen Leslie of Physios for ME.
Why 4? Well, it’s a great book about ME – aimed primarily at physios, but so well researched, up to date and clearly written, that if you want to raise the understanding of any of the professionals working with you, or even your friends or family members, this book does the job.
So we’ve been saving up and buying them to give away – so far to: our Health Board’s Exec member for Neurology and Therapies (she invited me in to meet her), the HB officer setting up the new extended Long Covid + service (includes ME), a neuro rehab consultant , a registrar, and our GP. These four books are for the physio and OT from the neuro team, and a psychologist, and A.N.Other. Can’t recommend the book highly enough.
I guessed that people who’ve heard just a bit about ME might associate it mainly with ‘fatigue’, and would think that’s to do with not having enough physical energy. Actually, ME is a multi-system illness producing multi-symptoms, and the ‘fatigue’ bit of it is both well beyond the kind that most of us experience, and can be both physical and neuro-cognitive.
Anyway, I thought I should check out the physical side of things first. What’s the latest science?
I guessed Physios for ME would know about that, and Karen Leslie kindly agreed to help me understand why an old bloke like me can hike 5 miles, puffing and panting his way up to Paxton’s Tower every morning, but our son who has very severe ME can’t even stand up, let alone walk out of his room.
Even after editing, the video of our discussion was >50 minutes long! Well, there was a lot to talk about. And it’s really worth a listen – get yourself a cuppa and do it.
Discussions at dawn interview with Karen Leslie
Karen explained that Physios for ME (there are 4 of them: Dr Nicola Clague-Baker, Dr Michelle Bull, Natalie Hilliard, and Karen) got together out of a shared professional experience of working with people with ME, and/or personal experience of being close to someone with the diagnosis.
We agreed that, in our experience, something that stands out in people with ME is their amazing psychological resilience in the face of adversity, and their desire and determination to try and get better.
Physios for ME are all very experienced professionals with different specialisms. As a specialist neurological physiotherapist , Karen works with people with many complex conditions, including stoke, brain injuries, MS and Parkinsons. She said:
“I treat lots and lots of really complex conditions, and wherever I go I know that my physio toolkit will help these people, and I can make a big difference. And I was pretty confident in that until I met somebody who had severe ME”.
She realised that lack of training and awareness means that she and her fellow physios in general have been poorly prepared to meet the needs of people with ME.
The difference with ME is the need to consider post-exertional malaise (PEM) – when multi-symptoms can be worsened and persist in a way which is out of all proportion to minimal ‘exertion’. It’s the stand-out feature of ME, but it’s poorly understood by health professionals.
Karen told me that sports scientists at the Workwell Foundation have used repeat Cardio-Pulmonary Exercise Tests (CPETs) to measure the difference between ME patients and healthy people, and to find a way of objectively measuring PEM. They found that the ME patients started working anaerobically (rather than aerobically) much sooner than the healthy participants.
These were patients whose ME was towards the ‘milder’ end of the severity spectrum (they couldn’t have taken part if they were ‘severe’), but even so, whereas the healthy ‘control group’ could do just as well on the second day as the first, the average recovery time for the ME patients was 2 weeks, and one had not recovered a year later.
The PEM effect is disabling, and multi-system, which is why some prefer the term post-exertional symptom exacerbation (PESE). Although the trigger, in this experiment, is physical exertion, the effect is not just physical ‘fatigue’, but also body pain, and neuro-cognitive-sensory symptoms, affecting the ability to think and communicate, or deal with light and sound, for example.
We also discussed the apparently bizarre PEM effect my daughter experiences – getting pain in her legs when trying to read – and learned that this was neither unique nor inexplicable.
Cognitive ‘exertion’, or exposure to sensory overload, can also cause an exacerbation of both neuro-cognitive-sensory and physical symptoms.
Karen explained that Physios for ME have encountered this phenomenon in their ‘feasibility study’, in which people with severe ME were visited at home and observed / measured when doing simple activities of daily living. Their observations were in line with Workwell’s results, but with more severe patients.
Unexpectedly, it was during a cognitive Maths challenge that the most people began working anaerobically, leading to physical symptoms including body pain.
PEM can only be relieved over time, with rest. But, if pushed too far, the person can be tipped into a longer lasting, more severe phase of the illness. This is why physiotherapists have to be aware of what’s happening physiologically in the ME patient, and take care not to trigger PEM.
“But that’s my job – to adapt how I’m working to make sure that I’m not causing that person any harm”, Karen said.
We talked about how physiotherapists have to find strategies other than Graded Exercise Therapy (GET), since NICE (National Institute for Clinical and Health Excellence) concluded in its 2021 revised guidance, that:
“…any programme using fixed incremental increases in physical activity or exercise (for example, graded exercise therapy), or physical activity or exercise programmes that are based on deconditioning and exercise avoidance theories, should not be offered to people with ME/CFS. The committee also wanted to reinforce that there is no therapy based on physical activity or exercise that is effective as a cure for ME/CFS.” (NG206 p78)
Karen gave lots of examples of how physiotherapists can assist people with ME, including helping them to understand energy management techniques – e.g. using pacing, and the value of ‘wearable devices’ and appropriate equipment.
She talked about the need for physiotherapists to be aware of the risk of PEM in ME patients, so that when exercise is appropriate or necessary, it can be used safely e.g. when the ME patient needs physiotherapy following an injury.
[N.B. And Physios for ME have recently published a one page leaflet to for people in that situation – a brief guide to give to your physiotherapist. Find it here in English and Welsh (and other languages).]
We went on to discuss Long Covid, and Physios for ME’s ambitions for research, and, of course, the book, which at that time was just being prepared for publication.
You can get it from the publisher: here as well as from bookshops and other on-line booksellers.
Catch up with Physios for ME’s resources, latest news and research at www.physiosforme.com
BIG THANKS! to Karen for agreeing to have a Discussion at Dawn with me, and for all she and Physios for ME are doing to try to make the sun rise for people with ME! Watch the video
The helpline will be closed from 5pm Thursday 26 March – 10am Tuesday 2 April 2024.
Normal hours are 10am – 7pm
For emotional support, the Samaritans can be contacted 24 hours a day, 7 days a week.
English – 116 123 – free number (24 hours a day, 7 days a week)
Cymraeg – 0808 164 0123 – free number (7am -11pm, 7 days a week)
Children and young people up to age 25 can also contact Meic by phone, email, SMS text and instant messaging.
8am to midnight, 7 days a week
As we observe International Long COVID Awareness Day on March 15th, WAMES and the World ME Alliance stands in solidarity with the millions worldwide living with Long COVID, many of whom are now being diagnosed with Myalgic Encephalomyelitis (ME). This day serves as a poignant reminder of and call-to-action for the millions around the globe grappling with the debilitating long-term consequences of the COVID-19 pandemic, that are far from over.
Long COVID describes a collection of lingering symptoms devastating the lives of millions of COVID-19 survivors. These symptoms persist in an estimated 10–20% of COVID-19 patients, regardless of infection severity, even after the patient no longer tests positive for the virus or antibodies. While recovery times for COVID-19 vary from person to person, Long COVID generally refers to cases where symptoms continue to persist for 90 days or more.
Increasing research into Long COVID demonstrates many similarities to other chronic illnesses known to be associated with viral triggers, such as Myalgic Encephalomyelitis (ME), postural orthostatic tachycardia syndrome (POTS), dysautonomia, mast cell activation syndrome (MCAS), and more.
Research now suggests that 50% of people with Long COVID meet the criteria for an ME diagnosis. The World ME Alliance estimates that the number of people living with ME worldwide has likely doubled since the beginning of the COVID-19 pandemic.
As this phenomenon continues to garner increased attention from the medical community and society at large, it is crucial to acknowledge the intersection of Long COVID and ME.
On International Long COVID Awareness Day, we urge individuals, healthcare providers, and policymakers to recognise the profound impact of Long COVID, ME, dysautonomia and other infection associated chronic conditions.
Take Action with a Long COVID organisation today:
At the World ME Alliance, we stand united with individuals affected by Long COVID on International Long COVID Awareness Day. By fostering understanding, advocating for support, and joining forces with organisations dedicated to these overlapping conditions, we can create a more compassionate and informed society.
Together, we strive for a future where everyone receives the care, support, and dignity they deserve
A study of children and young people in the UK pre-pandemic found that investigation, referral and management of those with suspected severe ME/CFS do not always meet NICE recommendations.
This suggests patients may be receiving suboptimal care since alternative diagnoses are not appropriately excluded and specialist care is not provided. The low number of young people receiving domiciliary visits or social services assessment/support limits their access to management.
The researchers conclude that further work should focus not only on determining the most effective treatments for children with severe ME/CFS but also on exploring the barriers to accessing these services and how these can be addressed.
WHAT IS ALREADY KNOWN ON THIS TOPIC
WHAT THIS STUDY ADDS
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
Research abstract:
Objective
Severe myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) in children and young people (CYP) is a little-understood condition which significantly impacts education, development and quality of life.
We used data from a population-wide surveillance study to explore the screening investigation, referral and management of suspected cases of paediatric severe ME/CFS.
Methods
A British Paediatric Surveillance Unit (BPSU) study reported cases of CYP with suspected severe ME/CFS between February 2018 and February 2019. Paediatricians reporting cases to BPSU and allied healthcare professionals in two large specialist paediatric ME/CFS centres were invited to complete questionnaires for CYP meeting the surveillance case definition. The study focused primarily on CYP with confirmed severe ME/CFS and the extent to which their care met NICE (The National Institute for Health and Care Excellence) recommendations but also considered separately those with probable or possible severe ME/CFS.
Results
This study includes a total of 92 CYP with suspected severe ME/CFS; 33 meeting criteria for severe ME/CFS and an additional 59 classified as probable or possible severe ME/CFS. For 16 possible cases, incomplete investigation to exclude alternative diagnoses prevented confirmation of a severe ME/CFS diagnosis.
Only 21 of 33 (64%) confirmed severe ME/CFS cases had been referred to specialist services. The management provided varied considerably between patients and four received nothing at all. Of the management provided, the most frequent approaches were medication (67%), activity management (61%) and physiotherapy (61%).
Domiciliary assessments and support, and social services referrals were received by 12% and 6% of confirmed severe cases. Similar proportions of management approaches were seen in probable/possible severe ME/CFS.
Conclusion
Full investigation is frequently incomplete in CYP with suspected severe ME/CFS and recommendations for referral and management are poorly implemented, in particular the needs of CYP who are unable to leave their home might be poorly met.
As we approach World ME Day 2024, WAMES and the World ME Alliance (WMEA) invites you to be a part of a new short film that aims to shed light on the reality of Myalgic Encephalomyelitis (ME).
The World Health Organization recognized ME 55 years ago, yet any treatment remains elusive, and millions more are now grappling with the aftermath of ME triggered by COVID-19. This global health crisis demands attention, and we need your voice to make a difference.
Take Part
Send us a short video of yourself reading out the script below.
This script has been developed by people with ME across four countries. We’ll join your videos together into one campaign film, to reach others and demonstrate that ME is a truly global health crisis. We’ll then use this to call on individuals, organisations and countries to join together as a #GlobalVoiceForME advocating for change.
Script for your video
“It’s 55 years since the World Health Organization officially recognised Myalgic Encephalomyelitis.
But there is still no cure. No treatments. And millions more are developing ME triggered by COVID-19.
Today, we estimate 55 million individuals worldwide are living with the debilitating effects of ME.
We demand recognition, research, and respect.
I am a [person with ME/ doctor/ researcher/ carer/ friend/ advocate/ family member/ nurse/ charity worker etc – tell us your relation to ME]
I am from [your country]
This is a global health crisis.
Take action with us for World ME Day.
Together, we are a Global Voice for ME.”
Severe ME – alternative participation
If it is difficult or impossible for you to read out a script, we still want you to participate. If you can, please upload a 5 second video of yourself looking directly into the camera. You don’t need to say anything.
We then aim to include this in the final cut, with subtitles that read “Many are too sick to speak”
Find out how to upload your video
The deadline for submissions is 1st April 2024
The DecodeME team posted an update on 7 March 2024
DecodeME will use small differences in the DNA of people with ME/CFS to look for biological causes of the disease.
We have an important project update to share with you.
DecodeME participants have done a great job completing questionnaires and returning spit samples. But the next step – extraction of DNA at UK Biocentre – has faced operational and capacity issues.
We have been working hard with UK Biocentre to resolve as many of these issues as possible and to avoid delays. While some issues were mitigated, it became obvious that we simply would not have enough time to perform all necessary data analyses by August 2024, the planned end date.
We discussed this situation with both our Scientific Advisory Board and funders. They agreed with our assessment and funding was awarded to extend the project until August 2025. This will give us sufficient time to finish the project.
We remain fully committed to completing this research to the highest possible scientific standards, ensuring that our findings are as robust as possible. We are acutely aware of the urgency to deliver the study results as soon as possible and we continue to work as hard as we can to fulfill these goals.
A message from our team:
“On the Patient and Public Involvement Steering Group, we recognise that this delay may be disappointing for you, as it is for us. We live with, and see the impact of, ME/CFS on a daily basis. We’re grateful the funders are continuing to support this project with additional funding. DecodeME will deliver results as quickly as possible and we remain hopeful that the study will give us clues that lead to treatments”. Sian Leary, DecodeME PPI Steering Group member.
Watch our video message below
What’s next?
We continue to formulate plans to build on DecodeME. This includes discussing with other researchers plans for the replication and potential validation of any findings, and working towards securing the longer term future of the DecodeME cohort of participants. We’ll share details of these plans as soon as we can.
We continue to be grateful for your support of, and engagement with, DecodeME. Your ongoing involvement, as a participant, continues to be essential for successfully completing the search for genetic causes of why people become ill with ME/CFS.
Find out more about the study from the website
Criticisms by 50+ international researchers and clinicians of the ME/CFS NICE guideline were published in July 2023 and available on open access. In February 2024 a response from NICE was published, behind a paywall. After much lobbying this was made freely available on 7 March 2024
“We outline how these opinions are based on a misreading or misunderstanding of the guideline process or the guideline, which provides a balanced and reasoned approach to the diagnosis and management of this challenging condition.”
“There is a lack of evidence supporting energy management in people with ME/CFS, and no evidence that it is a ‘cure’. But there is also no signal of harm or deterioration with energy management programmes, unlike with GET.”
“The new guideline on ME/CFS was produced by an independent committee of clinicians who look after people with the condition, and people with lived experience of ME/CFS. Development followed a transparent process that conformed to recognised standards for guideline development, including extensive consultation with stakeholders prior to publication.
All evidence needs interpretation: evidence alone cannot determine the content of a recommendation. Criticisms of the guideline discussed in this paper are misplaced. The guideline has been welcomed and widely accepted by patient groups and clinicians leading services for people with ME/CFS in the UK.
We hope that the guideline will lead to better care and the development of more effective therapies for people with ME/CFS.”
NICE guideline on ME/CFS: robust advice based on a thorough review of the evidence, by Peter Walter Barry, Kate Kelley, Toni Tan, Ilora Finlay in Journal of Neurology, Neurosurgery and Psychiatry 8 February 2024. [doi: 10.1136/jnnp-2023-332731]
MERUK: NICE responds to claims of “a controversial U-turn” on GET and CBT
Video interview with David Tuller: Adam Lowe Explains the NICE Response to Uninformed “Eight Anomalies” Critique of ME/CFS Guidelines
Abstract
In 2021, the National Institute for Health and Care Excellence produced an evidence-based guideline on the diagnosis and management of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a disabling long-term condition of unknown cause. The guideline provides clear support for people living with ME/CFS, their families and carers, and for clinicians. A recent opinion piece published in the journal suggested that there were anomalies in the processing and interpretation of the evidence when developing the guideline and proposed eight areas where these anomalies were thought to have occurred. We outline how these opinions are based on a misreading or misunderstanding of the guideline process or the guideline, which provides a balanced and reasoned approach to the diagnosis and management of this challenging condition.
https://doi.org/10.1136/jnnp-2023-332731
I approached Dr Nina Muirhead (Doctors with ME) and Karen Leslie (Physios for ME) to lead off the first two discussions, and, to my delight, they both said “Yes”!
Unfortunately, ME has had a difficult and controversial history, to the great detriment of patients (it’s time this was put right!), and it’s an illness which is still often misunderstood by the public, and by health professionals who have traditionally received very little and/or poor training about it. So, I gave the first Discussion at Dawn a straightforward title, ‘What is ME?’ – it seemed the obvious place to start.
As a person with ME, a senior doctor and medical educator, Dr Muirhead was really well placed to give an introduction to this question in an up-to-date, easy-to-understand way. She talked about the growing biomedical research evidence which shows that ME is an illness affecting multiple systems in the body, causing a wide range of debilitating symptoms which can profoundly impact people’s lives. She explained the meaning of post-exertional malaise, the ‘cardinal symptom’ of ME, its debilitating impact, and how difficult it can be to manage.
We discussed the levels of severity at which the illness can be experienced, something not widely understood, even in the medical profession. Dr Muirhead said,
“…the type of existence that a person with very severe ME has, is almost aligned with end-of-life care for very sick patients who are dying”.
No hyperbole here – our own severely affected son has spent time in palliative care.
At this point in our discussion there was a long pause whilst we both got a bit upset.
Dr Muirhead had been severely affected, herself, but had improved to the point where she now described herself as being at the ‘Mild’ level (Take a look at the severity levels in NICE Guidelines).
I asked what this meant in terms of her ability to function on a day-to-day basis. She explained that being ‘Mild’ meant that she had been able to return to work as a dermatological surgeon on a part-time basis, but this was dependent on her being able to plan ahead and build in days of rest, doing her admin from home, actually taking all week to do a half-time job.
She felt lucky that she’d been able to manage some short walks in the woods with her family again, but other activities she used to enjoy, like running and cycling, were out of reach. She was still dealing with ME symptoms every day, including sore throats, headaches, muscle pain, brain fog and cognitive difficulties (including reading for work) and her symptoms were fluctuating week on week, month on month. So, not so mild, after all!
I asked about Long Covid, and whether its emergence had led to a better understanding of ME. She explained that a significant subset of people with Long Covid are experiencing a wide range of symptoms which are
“…fitting into more of an ME-type picture…The only difference is that we know that Covid was the trigger for their chronic, post-viral, multi-system disease”.
The government needs to invest in biomedical research, she added, to get to the bottom of post-viral illness, because, with up to a million people in the UK estimated to be affected by Long Covid of whom about 400,000 are still experiencing symptoms after 3 years, there could be significant economic implications for the country in years to come.
Her personal experience of ME, an illness she knew almost nothing about before she became ill herself, has led to Dr Muirhead becoming an advocate for better medical education about the illness. Currently the condition is
“…not only poorly understood, it’s poorly diagnosed with patients often waiting years for a diagnosis, and it’s poorly taught”, she said.
Her own research has revealed that the majority of UK undergraduate medical programmes have no taught element on ME. So, she has written a free on-line accredited CPD training module to start addressing this deficit. You can find it here
She’s also a director of Doctors with ME, a global professional association for medical professionals in the field – led by medics who suffer from ME themselves; Chair of the CFS/ME Research Collaborative Medical Education Working Group; a rep on the Forward ME group; an expert witness to the last review of the NICE ME/CFS Guideline.
A big THANK YOU to Dr Nina Muirhead for taking part in #500miles4ME and for all she’s doing to help raise awareness and improve the lives of people with ME.
A couple of comments we received from people who’d watched this Discussion at Dawn:
“Thank you so much for this. I have been living with ME for 20 years, and it is so encouraging and validating that people, particularly in the medical profession, are pushing for it to be taken seriously.”
“Thank you for doing this. I’ve been more or less bedbound for 6 years. Not left the house in 2 years. No carer. Human contact overwhelms my system. I just do what I can to survive.”
Next time in Blog 4: I’ll talk about my Discussion at Dawn with Karen Leslie of Physios for ME, when I asked her “How come an old bloke like me, with dodgy knees, can walk 5 miles a day, push and puff my way up this steep hill, go home, have a rest, come back tomorrow and do it all again, and every day I’ll be getting fitter and it’ll be getting easier – but it’s not like that for people with ME?
See all Discussions at dawn interviews
Researchers for Melbourne Australia reviewed research into both ME/CFS and Long COVID.
“Research into both disorders is mutually beneficial as Long COVID can provide a unique opportunity to study early disease changes and map these changes over the duration of the disease,” Dr Annesley said.
Conversely the ME/CFS research, which typically involves patients with a longer disease duration, may provide clues as to the future disease pathology of Long COVID.”
The review found many similarities between the 2 conditions but with many questions still to be answered – they list key topics for further study. They believe that measuring certain types of RNA in ME/CFS could be the most accurate and clinically practicable biomarker, worthy of further research.
Highlights
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic illness often triggered by an initiating acute event, mainly viral infections. The transition from acute to chronic disease remains unknown, but interest in this phenomenon has escalated since the COVID-19 pandemic and the post-COVID-19 illness, termed ‘long COVID’ (LC).
Both ME/CFS and LC share many clinical similarities. Here, we present recent findings in ME/CFS research focussing on proposed disease pathologies shared with LC. Understanding these disease pathologies and how they influence each other is key to developing effective therapeutics and diagnostic tests.
Given that ME/CFS typically has a longer disease duration compared with LC, with symptoms and pathologies evolving over time, ME/CFS may provide insights into the future progression of LC.
LaTrobe News: Chronic fatigue offers clues to Long COVID, News, La Trobe University
